非洲南部年轻女性PrEP摄取、持续性、依从性及回顾性药物水平反馈的影响:HPTN 082随机对照试验
HPTN 082在非洲南部三国开展,评估16-25岁HIV阴性性活跃女性对PrEP的摄取、持续性和药物水平反馈对依从性的影响。95%启动PrEP,55%持续至12个月,6个月时高依从比例两组无差异。HIV发病率为1.0/100人年。
要点
- 非洲年轻女性PrEP启动率高(95%),但12个月持续性仅55%。
- 6个月时高依从(TFV-DP≥700 fmol/punch)比例两组均约21-22%。
- 药物水平反馈未提高6个月高依从比例(aOR 0.92,95%CI 0.55-1.34,p=0.76)。
核心结论
- PrEP启动率高,超过一半参与者持续至12个月,多数女性6个月内可检测到TFV-DP,约五分之一达高依从。
- 前3个月药物水平反馈未增加6个月时高依从比例。
- 该人群HIV发病率为1.0/100人年,可治愈STI患病率39%,PrEP依从性中等。
研究设计与样本
- HPTN 082为随机对照试验,2016年10月至2018年10月在南非开普敦、约翰内斯堡和津巴布韦哈拉雷开展。
- 纳入451名16-25岁性活跃HIV阴性女性,提供PrEP并随访12个月。
- 接受PrEP者随机分为标准支持组(咨询、双向短信、依从俱乐部)或增强支持组(基于干血斑TFV-DP水平的依从反馈)。
- 主要结局为6个月时高依从(TFV-DP≥700 fmol/punch),比较两组。
主要发现
- 451名女性中位年龄21岁,39%有可治愈STI。
- 95%启动PrEP,其中55%至12个月无中断续药。
- 有DBS者中,84%第3个月、57%第6个月、31%第12个月可检测到TFV-DP。
- 6个月时增强组36/179(21%)高依从,标准组40/184(22%)高依从(aOR 0.92,95%CI 0.55-1.34,p=0.76)。
- 4名女性感染HIV(发病率1.0/100人年),血清转换时或之前TFV-DP低或不可测,均无替诺福韦或恩曲他滨耐药突变。
关键数值与推荐
- 高依从定义为TFV-DP≥700 fmol/punch。
- 持续性定义为12个月内无PrEP暂停或错过访视。
临床怎么用
- 非洲年轻女性PrEP启动意愿高,但需加强持续性支持。
- 药物水平反馈未显著改善依从性,需探索其他支持策略。
- 该人群STI患病率高,应整合STI筛查与PrEP服务。
局限性
- 研究把握度有限,无法检测药物水平反馈对依从性的中等效应。
- 研究开展时对PrEP的认知有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective and an important prevention tool for African adolescent girls and young women (AGYW), but adherence and persistence are challenging. PrEP adherence support strategies for African AGYW were studied in an implementation study. METHODS AND FINDINGS: HIV Prevention Trials Network (HPTN) 082 was conducted in Cape Town, Johannesburg (South Africa) and Harare (Zimbabwe) from October 2016 to October 2018 to evaluate PrEP uptake, persistence, and the effect of drug level feedback on adherence. Sexually active HIV-negative women ages 16-25 were offered PrEP and followed for 12 months; women who accepted PrEP were randomized to standard adherence support (counseling, 2-way SMS, and adherence clubs) or enhanced adherence support with adherence feedback from intracellular tenofovir-diphosphate (TFV-DP) levels in dried blood spots (DBS). PrEP uptake, persistence through 12 months (no PrEP hold or missed visits), and adherence were assessed. The primary outcome was high adherence (TFV-DP ≥700 fmol/punch) at 6 months, compared by study arm. Of 451 women enrolled, median age was 21 years, and 39% had curable sexually transmitted infections (STIs). Most (95%) started PrEP, of whom 55% had uninterrupted PrEP refills through 12 months. Of those with DBS, 84% had detectable TFV-DP levels at month 3, 57% at month 6, and 31% at month 12. At 6 months, 36/179 (21%) of AGYW in the enhanced arm had high adherence and 40/184 (22%) in the standard adherence support arm (adjusted odds ratio [OR] of 0.92; 95% confidence interval [CI] 0.55, 1.34; p = 0.76). Four women acquired HIV (incidence 1.0/100 person-years), with low or undetectable TFV-DP levels at or prior to seroconversion, and none of whom had tenofovir or emtricitabine resistance mutations. The study had limited power to detect a modest effect of drug level feedback on adherence, and there was limited awareness of PrEP at the time the study was conducted. CONCLUSIONS: In this study, PrEP initiation was high, over half of study participants persisted with PrEP through month 12, and the majority of young African women had detectable TFV-DP levels through month 6 with one-fifth having high adherence. Drug level feedback in the first 3 months of PrEP use did not increase the proportion with high adherence at month 6. HIV incidence was 1% in this cohort with 39% prevalence of curable STIs and moderate PrEP adherence. Strategies to support PrEP use and less adherence-dependent formulations are needed for this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT02732730.
引用
- Celum C, Hosek S, Tsholwana M, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Med. 2021. PMID: 34143779. doi:10.1371/journal.pmed.1003670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。